ArticleJournal of translational medicine2025
Dynamin 1 promotes colorectal cancer progression by activating the PI3K/Akt signaling pathway.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- High-fat diet-responsive DNM1 promotes hepatocellular carcinoma progression and predicts poor prognosis in viral-associated patients.American journal of cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundUncontrolled proliferation, local invasion, and distant metastasis are hallmarks of malignancies, and they play crucial roles in tumor progression. Dynamin 1 (DNM1) is a member of the dynamin guanosine-5′-triphosphatease (GTPase) subfamily that regulates membrane fission, cytokinesis, and vesicle secretion. However, its function in colorectal-cancer (CRC) progression remains unclear.
methodsWe used public datasets and a tissue microarray (TMA) cohort to analyze differential expression of DNM1 between CRC tissues and adjacent nontumor tissues (NTs). The role of DNM1 in CRC cells was determined by in vitro experiments, including colony formation, Cell Counting Kit-8 (CCK-8), and Transwell assays. Ribonucleic acid sequencing (RNA-seq) and bioinformatics analysis were performed to investigate mechanisms that DNM1 may be involved in. KLF5 was identified as an upstream transcriptional activator of DNM1 through a combination of bioinformatic screening and functional experiments. Xenograft and metastatic models were established to investigate the effects of DNM1 on tumor growth and metastasis.
resultsWe found that DNM1 expression was upregulated in CRC tissues, which significantly correlated with poor patient prognoses. DNM1 overexpression (OE) enhanced the proliferation, migration, and invasion capabilities of CRC cells both in vitro and in vivo, whereas DNM1 knockdown (KD) yielded the opposite results. Mechanistically, we identified Krüppel-like factor 5 (KLF5) as an upstream transcription factor that activates DNM1 transcription. Furthermore, DNM1 was shown to mediate the activation of epithelial–mesenchymal transition (EMT) and the phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) signaling pathway.
conclusionDNM1 promotes CRC progression and malignant phenotypes, and targeting the KLF5/DNM1/Akt axis may represents a promising strategy to improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.